| Company | Amount/Round | Lead Investors | Description |
|---|---|---|---|
| CoLucid CoLucid Pharmaceuticals Indiana | $25M Second | Care Capital | The financing will be used to develop COL-144, a migraine compound, and to advance preclinical pipeline candidates that target neurological and psychiatric disorders. |
| Immune Design Seattle | $18M First | Alta Partners, The Column Group and Versant Ventures | The vaccine company is developing therapies targeting dendritic cells, which control the human immune response system. And its researchers plan to develop new vaccines as well as enhance existing therapies. |
| Limerick BioPharma South San Francisco | $15 Unknown | Arch Venture Partners, Sevin Rosen Funds and Altitude Funds | Limerick BioPharma will advance its work on the bioavailability of drugs. |
CoLucid gets $25M